Prospective Grant of Exclusive License: North-2'-Deoxy-Methanocarbathmydines as Antiviral Agents Against Poxvirus, 58728 [05-20242]
Download as PDF
<![CDATA[
58728
Federal Register / Vol. 70, No. 194 / Friday, October 7, 2005 / Notices
MSC 7844, Bethesda, MD 20892, (301) 435–
2212, josephru@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel,
Bioengineering Research Partnerships—
Biomedical Sensing.
Date: October 27, 2005.
Time: 1 p.m. to 2 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Pushpa Tandon, PhD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5104,
MSC 7854, Bethesda, MD 20892, (301) 435–
2397, tandonp@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, RIBT
Member Conflicts.
Date: October 27, 2005.
Time: 1 p.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: George M. Barnas, PhD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health 6701 Rockledge Drive, Room 2180,
MSC 7818, Bethesda, MD 20892, (301) 435–
0696, barnasg@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Nuclear
Membrane Proteins.
Date: October 27, 2005.
Time: 2 PM to 3 PM.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health; 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Jonathan Arias, PHD,
Scientific Review Administrator, National
Institutes of Health, 6701 Rockledge Drive,
Room 5170 MSC 7840, Bethesda, MD 20892,
301–435–2406, ariasj@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Approaches
in Cancer Therapeutics.
Date: October 27, 2005.
Time: 3 PM to 5 PM.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Joanna M. Watson, PHD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6046–G,
MSC 7804, Bethesda, MD 20892, 301–435–
1048, watsonjo@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
VerDate Aug<31>2005
18:27 Oct 06, 2005
Jkt 208001
Dated: September 30, 2005.
Anthony M. Coelho, Jr.
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–20254 Filed 10–6–05; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive
License: North-2’-DeoxyMethanocarbathmydines as Antiviral
Agents Against Poxvirus
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: This is notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
404.7(a)(1)(i), that the National
Institutes of Health (NIH), Department
of Health and Human Services (HHS), is
contemplating the grant of an exclusive
license to practice the following
invention as embodied in the following
patent applications: HHS Ref. No. E–
047–2005; U.S. Provisional Patent
Application Number 60/684,811, filed
on May 25, 2005 to N&N Scientific,
having a place of business in Maryland
but incorporated in Illinois. The patent
rights in these inventions have been
assigned to the United States of
America.
DATES: Only written comments and/or
application for a license which are
received by the NIH Office of
Technology Transfer on or before
December 6, 2005 will be considered.
ADDRESSES: Requests for a copy of the
patent application, inquiries, comments
and other materials relating to the
contemplated license should be directed
to: Robert M. Joynes, Office of
Technology Transfer, National Institutes
of Health, 6011 Executive Boulevard,
Suite 325, Rockville, MD 20852–3804;
E-mail: joynesr@od.nih.gov; Telephone:
(301) 594–6565; Facsimile: (301) 402–
0220.
SUPPLEMENTARY INFORMATION: The
prospective exclusive license will be
royalty bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR 404.7. The prospective
exclusive license may be granted unless,
within 60 days from the date of this
published Notice, NIH receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR 404.7. The
field of use may be limited to the
treatment of poxviruses.
PO 00000
Frm 00067
Fmt 4703
Sfmt 4703
The subject invention relates to a
method for the prevention or treatment
of poxvirus infection by administering
an effective amount of an antiviral agent
comprising a carbocyclic 2’deoxynucleoside analog (as described in
U.S. Patent Nos. 5,629,454 and
5,869,666) to an individual in need
thereof. North-methanocarbathymidine
(N–MCT), a thymidine analog with a
pseudosugar moiety locked in the
northern conformation, which was
previously shown to exert strong
activity against herpes simplex virus
types 1 and 2, has been identified as
exhibiting potent activity against
poxviruses. N–MCT effectively blocks
poxvirus synthesis through its
phosphorylated metabolite, which is
more efficiently produced in poxvirusinfected cells. This compound is
approximately seven times more potent
than cidofovir against vaccinia and
cowpox in cell culture. The higher
potency and target specificity of N–MCT
against poxvirus, as well as its high
margin of safety, makes it a highly
desirable agent against the poxviridae
family. In addition, the mechanism of
N–MCT may be different from that of
cidofovir, making it even more desirable
due to the scarcity of the potential
available efficacious anti-pox agents
currently under development.
The licensed territory will be
exclusive worldwide.
Properly filed competing applications
for a license filed in response to this
notice will be treated as objections to
the contemplated license. Comments
and objections submitted in response to
this notice will not be made available
for public inspection, and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
Dated: September 27, 2005.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 05–20242 Filed 10–6–05; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
Office of the Secretary
Senior Executive Service Performance
Review Board
Office of the Secretary, DHS.
Notice.
AGENCY:
ACTION:
SUMMARY: This notice announces the
appointment of the members of the
Senior Executive Service Performance
E:\FR\FM\07OCN1.SGM
07OCN1
]]>Agencies
[Federal Register Volume 70, Number 194 (Friday, October 7, 2005)]
[Notices]
[Page 58728]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-20242]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License: North-2'-Deoxy-
Methanocarbathmydines as Antiviral Agents Against Poxvirus
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37
CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH),
Department of Health and Human Services (HHS), is contemplating the
grant of an exclusive license to practice the following invention as
embodied in the following patent applications: HHS Ref. No. E-047-2005;
U.S. Provisional Patent Application Number 60/684,811, filed on May 25,
2005 to N&N Scientific, having a place of business in Maryland but
incorporated in Illinois. The patent rights in these inventions have
been assigned to the United States of America.
DATES: Only written comments and/or application for a license which are
received by the NIH Office of Technology Transfer on or before December
6, 2005 will be considered.
ADDRESSES: Requests for a copy of the patent application, inquiries,
comments and other materials relating to the contemplated license
should be directed to: Robert M. Joynes, Office of Technology Transfer,
National Institutes of Health, 6011 Executive Boulevard, Suite 325,
Rockville, MD 20852-3804; E-mail: joynesr@od.nih.gov; Telephone: (301)
594-6565; Facsimile: (301) 402-0220.
SUPPLEMENTARY INFORMATION: The prospective exclusive license will be
royalty bearing and will comply with the terms and conditions of 35
U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be
granted unless, within 60 days from the date of this published Notice,
NIH receives written evidence and argument that establishes that the
grant of the license would not be consistent with the requirements of
35 U.S.C. 209 and 37 CFR 404.7. The field of use may be limited to the
treatment of poxviruses.
The subject invention relates to a method for the prevention or
treatment of poxvirus infection by administering an effective amount of
an antiviral agent comprising a carbocyclic 2'-deoxynucleoside analog
(as described in U.S. Patent Nos. 5,629,454 and 5,869,666) to an
individual in need thereof. North-methanocarbathymidine (N-MCT), a
thymidine analog with a pseudosugar moiety locked in the northern
conformation, which was previously shown to exert strong activity
against herpes simplex virus types 1 and 2, has been identified as
exhibiting potent activity against poxviruses. N-MCT effectively blocks
poxvirus synthesis through its phosphorylated metabolite, which is more
efficiently produced in poxvirus-infected cells. This compound is
approximately seven times more potent than cidofovir against vaccinia
and cowpox in cell culture. The higher potency and target specificity
of N-MCT against poxvirus, as well as its high margin of safety, makes
it a highly desirable agent against the poxviridae family. In addition,
the mechanism of N-MCT may be different from that of cidofovir, making
it even more desirable due to the scarcity of the potential available
efficacious anti-pox agents currently under development.
The licensed territory will be exclusive worldwide.
Properly filed competing applications for a license filed in
response to this notice will be treated as objections to the
contemplated license. Comments and objections submitted in response to
this notice will not be made available for public inspection, and, to
the extent permitted by law, will not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: September 27, 2005.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 05-20242 Filed 10-6-05; 8:45 am]
BILLING CODE 4140-01-P
